Alpha Cognition Inc. Common Stock ACOG
i
Market dataready · fetched 2026-11-11T13:52:34.654Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-02-19
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:00:00.122544757Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-11T13:43:58.646041+00:00
Alpha Cognition Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 7.86 | 81.3% | 21.6% | |||
| 35Δ | 8.49 | 89.9% | 20.2% | |||
| 40Δ | 9.12 | 98.6% | 18.9% | |||
| 45Δ | 9.99 | 74.2% | 25.1% | 9.75 | 107.3% | 17.5% |
| 50Δ | 9.53 | 80.2% | 23.1% | 10.31 | 107.6% | 15.5% |
| 55Δ | 9.06 | 86.3% | 21.1% | 10.83 | 102.3% | 13.0% |
| 60Δ | 8.59 | 92.3% | 19.2% | 11.35 | 97.0% | 10.5% |
| 65Δ | 8.12 | 98.4% | 17.2% | 11.87 | 91.7% | 8.0% |
| 70Δ | 7.65 | 104.4% | 15.2% | 12.39 | 86.4% | 5.5% |
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.86
- IV
- 81.3%
- B/E move
- 21.6%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.49
- IV
- 89.9%
- B/E move
- 20.2%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.12
- IV
- 98.6%
- B/E move
- 18.9%
45Δ
- Pseudo strike
- 9.99
- IV
- 74.2%
- B/E move
- 25.1%
- Pseudo strike
- 9.75
- IV
- 107.3%
- B/E move
- 17.5%
50Δ
- Pseudo strike
- 9.53
- IV
- 80.2%
- B/E move
- 23.1%
- Pseudo strike
- 10.31
- IV
- 107.6%
- B/E move
- 15.5%
55Δ
- Pseudo strike
- 9.06
- IV
- 86.3%
- B/E move
- 21.1%
- Pseudo strike
- 10.83
- IV
- 102.3%
- B/E move
- 13.0%
60Δ
- Pseudo strike
- 8.59
- IV
- 92.3%
- B/E move
- 19.2%
- Pseudo strike
- 11.35
- IV
- 97.0%
- B/E move
- 10.5%
65Δ
- Pseudo strike
- 8.12
- IV
- 98.4%
- B/E move
- 17.2%
- Pseudo strike
- 11.87
- IV
- 91.7%
- B/E move
- 8.0%
70Δ
- Pseudo strike
- 7.65
- IV
- 104.4%
- B/E move
- 15.2%
- Pseudo strike
- 12.39
- IV
- 86.4%
- B/E move
- 5.5%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 187.36% | |
| 207.84% | |
| 267.91% |
Biotechnology
ACRS
Description unavailable
More →ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and…
More →AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in…
More →AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The…
More →AKTS
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures and sells radio frequency (RF) filter products for the wireless mobile device…
More →AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve…
More →